Targeted radionuclide therapy for patients with metastatic pheochromocytoma and paraganglioma: from low-specific-activity to high-specific-activity iodine-131 …
C Jimenez, W Erwin, B Chasen - Cancers, 2019 - mdpi.com
Low-specific-activity iodine-131–radiolabeled metaiodobenzylguanidine (I-131-MIBG) was
introduced last century as a potential systemic therapy for patients with malignant …
introduced last century as a potential systemic therapy for patients with malignant …
Molecular imaging and therapy for neuroendocrine tumors
H Desai, S Borges-Neto, TZ Wong - Current treatment options in oncology, 2019 - Springer
Opinion statement Neuroendocrine tumors (NETs) are relatively rare, with 12,000–15,000
new cases diagnosed annually in the USA. Although NETs are a diverse group of …
new cases diagnosed annually in the USA. Although NETs are a diverse group of …
Norepinephrine-transporter-targeted and DNA-co-targeted theranostic guanidines
ZP Kortylewicz, DW Coulter, G Han… - Journal of Medicinal …, 2019 - ACS Publications
High risk neuroblastoma often recurs, even with aggressive treatments. Clinical evidence
suggests that proliferative activities are predictive of poor outcomes. This report describes …
suggests that proliferative activities are predictive of poor outcomes. This report describes …